ClinicalTrials.gg
RecruitingNCT05598593Updated Oct 28, 2022

Modified TBF Regimen as Conditioning Regimen Prior to Allo-HSCT for T-ALL/LBL

A Phase 2 interventional study of cytarabine+thiotepa+ fludarabine + busulfan in Cytarabine+Thiotepa + Fludarabine + Busulfan and T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma, sponsored by First Affiliated Hospital of Zhejiang University. Recruiting at 1 site in China. Open to participants aged 4 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-10-28.

Sponsored by First Affiliated Hospital of Zhejiang University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started Oct 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
4 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in China — 27 open to participants now, 28 under way, 4 of them phase 3. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · China.

Planned enrollment
9th of 50
70 · median 30
Started
2022
with 6 others
Phase 2
8 of 51
7 open now
Primary completion
2024-09
later than 1 of 27 live
Registered
26th of 51
by date

Among the 51 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in China, this one is the 9th largest by planned enrollment of the 50 interventional ones that give a count, is one of 7 that started in 2022, is one of 8 in phase 2, reaches primary completion later than 1 of the 27 other live ones, and was the 26th registered.

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

421 studies on the registry are indexed under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; 75 are open to participants now.

Browse Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

27 of the 51 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in China are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 58 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 23 (40%) set no upper age limit and 30 (52%) stop at 75 or younger; 35 take children under 18; 1 takes healthy volunteers.

This study: 4 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in China, or all of them as a file.
02

Study summary

T cell acute lymphoblastic leukemia (T-ALL)/Lymphoblastic lymphoma (LBL) is a hematological malignancy caused by malignant transformation and clonal expansion of T-lineage precursor cells. The long-term cure rate of pediatric patients with T-ALL/LBL reaches 90%, but long-term survival of adult patients is less than 60%. Moreover, patients with high-risk factors such as PTEN/NRAS gene mutation, early T cell precursor (ETP) phenotype or positive minimal residual disease (MRD) have high rates of chemoresistance and dismal outcome. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can significantly improve the prognosis of high-risk T-ALL/LBL. Total body irradiation (TBI)-based conditioning chemotherapy regimen is the preferred regimen for allo-HSCT in children and young adults with ALL because of lower relapse rates and satisfactory survival. Different from children, the non-relapse-related mortality (NRM) after TBI-based preconditioning in adults (especially those >35 years old) was reported as high as 38%. In addition, serious sequelae after TBI seriously affect the quality of life and non-radiation conditioning chemotherapy regimens are urgently needed for T-ALL/LBL. The reported recurrence rates after BUCY (busulfan + cyclophosphamide) conditioning regimen for T-ALL as 41.2%. -56.7% and long-term survival was only 30-50%. Thiotepa is an ethyleneimine alkylating agent with anti-tumor effects and immunosuppressive effects, thus is widely used in conditioning regimen before HSCT. Retrospective paired analysis from EBMT indicated conditioning regimen thiotepa achieved similar relapse rates, long-term survival and faster granulocyte and platelet engraftment than TBI regimen. A recent retrospective study of childhood ALL from Turkey also reported that the TBF(thiotepa + fludarabine + busulfan) regimen had a recurrence rate of only 11.9% , a non-relapse mortality rate of 14.0% and a long-term survival of 79.1%. Data from a large retrospective paired study suggested TBF regimen can significantly reduce the relapse rate of acute myeloid leukemia after the first remission (HR=0.4, CI 0.2-0.7, P = .02) without increasing treatment related deaths compared with the traditional BUCY regimen. Based on these data, we modified the TBF regimen with additional cytarabine for allo-HSCT in T-ALL/LBL with expection to reduced disease relapse and improved long-term survival.

03

Conditions studied

  • Cytarabine+Thiotepa + Fludarabine + Busulfan
  • T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma

Keywords

  • allogeneic hematopoietic stem cell transplantation
  • T cell Acute Lymphoblastic Leukemia/Lymphoblastic lymphoma
  • thiotepa
04

Who can participate

Ages eligible
4 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age younger than 65 years
  2. Patients diagnosed with T cell acute lymphoblastic leukemia/lymphoma , T-ALL/LBL according to WHO diagnostic criteria.
  3. Patients who have donors and plane to accept hematopoietic stem cell transplantation treatment.
  4. body status score 0-2.
  5. Good organ function level: (neutrophil absolute value >=1.0x10\^9/ L; >=30x10\^9/L; HB >=80g/L; Tibil \<=1.5 ; / AST \<=2.5 ULN; bun / Cr \<=1.5 ULN; >=50%).
  6. Patients who voluntarily participate in the clinical trial, understand the research procedure and can sign the in writing.

Exclusion criteria

Exclusion Criteria:

  1. Patients who with severe cardiac insufficiency, cardiac EF is less than 60%; or severe arrhythmia, the investigator can not tolerate conditioning chemotherapy;
  2. In patients with severe pulmonary insufficiency (obstructive and / or restrictive ventilation disorders), the researchers evaluated the patients who could not tolerate conditioning chemotherapy;
  3. Patients with severe liver function impairment and liver function indexes (alt, ) more than 3 were evaluated as intolerant of conditioning chemotherapy;
  4. In patients with severe renal insufficiency, the renal function index (CR) is more than 2 times of the upper limit of the normal value (ULN), or the 24-hour rate (CR) is less than 50ml / min, the researchers evaluated that they could not tolerate conditioning chemotherapy;
  5. In patients with severe active infection, the researchers evaluated that they could not tolerate conditioning chemotherapy;
  6. Patients who had allergic reactions or serious adverse reactions in the previous use of pretreatment related drugs could not be included in the study.
  7. Other reasons why the researchers could not be selected.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Modified TBF Conditioning Regimen

    thiotepa 5mg/kg/d d-9 to d-8, cytarabine 0-4.0 g/m2/d d-7 to d-6(adjusted according to patients' age and HCT-CI index), fludarabine 30mg/m2/d d-7 to d-3, busulfan 3.2mg/m2/d d-5 to d-3

    Drug: cytarabine+thiotepa+ fludarabine + busulfan

Interventions

06

What researchers measure

Primary outcomes

  1. Disease free survival

    2-year DFS

    Time frame: 2 year

Secondary outcomes

  1. incidence of toxic reaction

    2-year incidence of toxic reaction

    Time frame: 2 year

  2. overall survival

    2-year OS

    Time frame: 2 year

  3. umulative incidence of relapse

    2-year incidence of relapse

    Time frame: 2 year

  4. ncidence of acute and or chronic graft verus host disease

    2-year incidence of cGVHD

    Time frame: 2 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Sep 2024, 23 months after the start.

Of 40 non-industry phase 2 interventional studies under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 97. This study's planned 23 months is below that.

Counting every sponsor, half of 43 studies reached it within 63 months; a quarter within 39 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2022
First posted
Oct 28, 2022
StartActual
Oct 23, 2022
Primary completionEst.
Sep 2024
CompletionEst.
Sep 2025
Last update
Oct 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05598593
Responsible party
Sponsor
First posted
Oct 28, 2022
Start date
Oct 23, 2022
Primary completion
Sep 2024 (estimated)
Completion
Sep 2025 (estimated)
Last update
Oct 28, 2022

Study contacts

Yi Luo, M.D.
Contact
luoyijr@163.com
+86057187233801
Luxin Yang, M.D.
Contact
yangluxin2016@126.com
+86057187233772
Yi Luo, M.D.
principal investigator · First Affilaated Hospital of Medical School of Zhejiang University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cytarabine · Thiotepa · Fludarabine · Busulfan

Start the discussion